Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph O'Connell

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Science (New York, N.Y.)|April 20, 2002
Control of the selectivity of the aquaporin water channel family by global orientational tuningEmad Tajkhorshid, Peter Nollert, Morten Ø Jensen, et al.
JACS Au|March 1, 2024
Shape-Selective Supramolecular Capsules for Actinide Precipitation and SeparationJoseph O'Connell-Danes, Bryne T Ngwenya, Carole A Morrison, et al.
Journal of Clinical Immunology|November 7, 2003
Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosisTerence M O'Connor, Joseph O'Connell, Darren I O'Brien, et al.
Current Opinion in Structural Biology|September 2, 2003
Glycerol facilitator GlpF and the associated aquaporin family of channelsRobert M Stroud, Larry J W Miercke, Joseph O'Connell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid TumorsEmiliano Calvo, Jean-Charles Soria, Wen Wee Ma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2014
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trialKeunchil Park, Byoung C Cho, Dong-Wan Kim, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialPasi A Jänne, Sai-Hong I Ou, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)Dong-Wan Kim, Edward B Garon, Aminah Jatoi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Science (New York, N.Y.)|April 20, 2002
Control of the selectivity of the aquaporin water channel family by global orientational tuningEmad Tajkhorshid, Peter Nollert, Morten Ø Jensen, et al.
JACS Au|March 1, 2024
Shape-Selective Supramolecular Capsules for Actinide Precipitation and SeparationJoseph O'Connell-Danes, Bryne T Ngwenya, Carole A Morrison, et al.
Journal of Clinical Immunology|November 7, 2003
Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosisTerence M O'Connor, Joseph O'Connell, Darren I O'Brien, et al.
Current Opinion in Structural Biology|September 2, 2003
Glycerol facilitator GlpF and the associated aquaporin family of channelsRobert M Stroud, Larry J W Miercke, Joseph O'Connell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid TumorsEmiliano Calvo, Jean-Charles Soria, Wen Wee Ma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2014
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trialKeunchil Park, Byoung C Cho, Dong-Wan Kim, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialPasi A Jänne, Sai-Hong I Ou, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)Dong-Wan Kim, Edward B Garon, Aminah Jatoi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.
Pageof 3